NasdaqCM:AXGNMedical Equipment
Why Axogen (AXGN) Is Down 10.1% After Avance FDA Win and 2026 Guidance Shift
In February 2026, Axogen reported full-year 2025 results showing sales of US$225.21 million versus US$187.34 million in 2024, alongside a wider net loss of US$15.70 million and basic loss per share of US$0.34, while also issuing 2026 guidance for at least 18% revenue growth to about US$265.70 million with a 74%–76% gross margin range.
These results coincided with U.S. FDA approval of Avance as the first biologic for peripheral nerve discontinuities with 12 years of market exclusivity, debt...